Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395223 | PMC |
| http://dx.doi.org/10.1016/j.amsu.2022.104391 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mpox: emergence following smallpox eradication, ongoing outbreaks and strategies for prevention.
Curr Opin Infect Dis
January 2025
Division of Pediatric Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Purpose Of Review: This review focuses on the temporal relationship between the discontinuation of the global smallpox eradication effort with the rise of mpox in Africa and worldwide. It also discusses the global 2022 clade II mpox epidemic and the current 2024 clade I mpox outbreak. Newer findings on viral evolution and pathogenesis, plus current and future strategies for disease prevention, are reviewed.
View Article and Find Full Text PDFMpox (monkeypox): a comprehensive updated of current epidemic evidence.
Sci One Health
December 2024
St Helier Hospital, Carshalton SM5 1AA, United Kingdom.
Mpox, formerly referred to as monkeypox, is a viral disease endemic to central Africa, resulting from the monkeypox virus (MPXV). This study provides a current overview of the Mpox epidemic as of 2024, emphasizing significant developments and epidemiological trends. The World Health Organization (WHO) initially designated a clade Ⅱb outbreak as a global health emergency in May 2022, which was subsequently managed through vaccination and public health interventions by May 2023.
View Article and Find Full Text PDFCurrent advances and challenges in mpox vaccine development: a global landscape.
Ther Adv Vaccines Immunother
January 2025
Virology Department of Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Given the surge in mpox outbreaks in 2022 and the advancements in domestic and international vaccine research, the effectiveness of smallpox vaccines in providing cross-protection against mpox remains crucial. Having learned from the COVID-19 pandemic, it is significant to continue evaluating existing vaccines to ensure their safety and efficacy. Developing new vaccines for widespread use against mpox and its emerging strains also serves as a preventive strategy in the ongoing battle against this dynamic infection.
View Article and Find Full Text PDFAntiviral activity of tecovirimat against monkeypox virus clades 1a, 1b, 2a, and 2b.
Lancet Infect Dis
January 2025
Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, Centre National de la Recherche Scientifique UMR3569, Paris 75015, France; Vaccine Research Institute, Paris, France. Electronic address:
Multiple gene-deletion vaccinia virus Tiantan strain against mpox.
Virol J
January 2025
Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130122, People's Republic of China.
Monkeypox virus (MPXV) is an important zoonotic pathogenic virus, which poses serious threats to public health. MPXV infection can be prevented by immunization against the variola virus. Because of the safety risks and side effects of vaccination with live vaccinia virus (VACV) strain Tian Tan (VTT), we constructed two gene-deleted VTT recombinants (TTVAC7 and TTVC5).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!